

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 10/18/2005

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/737,328	12/16/2003	Satoru Kuhara	JG-YY-4946D-C/500569.	6127	
26418 7	590 10/18/2005		EXAMINER		
REED SMITH, LLP			LU, FRANK WEI MIN		
ATTN: PATENT RECORDS DEPARTMENT 599 LEXINGTON AVENUE, 29TH FLOOR			· ART UNIT	PAPER NUMBER	
NEW YORK, NY 10022-7650			1634		

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Refore the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/737,328	KUHARA ET AL.		
Examiner	Art Unit		
Frank W. Lu	1634		

Before the Filling of all Appeal Brief	Examiner	Art Unit					
	Frank W. Lu	1634					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED 19 September 2005 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
 The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods: The period for reply expires 6 months from the mailing date 	the same day as filing a Notice of wing replies: (1) an amendment, aff tice of Appeal (with appeal fee) in ce with 37 CFR 1.114. The reply must of the final rejection.	Appeal. To avoid aba idavit, or other evider compliance with 37 C ust be filed within one	nce, which FR 41.31; or (3) of the following				
no event, however, will the statutory period for reply expire I	b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN						
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7		FIRST KEPLT WAS F	ILED MILLIN				
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	on which the petition under 37 CFR 1.1 tension and the corresponding amount shortened statutory period for reply origing than three months after the mailing date.	of the fee. The approprinally set in the final Offi te of the final rejection, of	ate extension fee ce action; or (2) as even if timely filed,				
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	ns of the date of e appeal. Since				
 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); 							
(c) They are not deemed to place the application in being appeal; and/or	·	ducing or simplifying	the issues for				
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		ected claims.					
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).							
5. Applicant's reply has overcome the following rejection(s):							
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 			1				
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 14-25. Claim(s) withdrawn from consideration:	☑ will not be entered, or b) ☐ will vided below or appended.	ll be entered and an e	explanation of				
AFFIDAVIT OR OTHER EVIDENCE							
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 	d sufficient reasons why the affiday	it or other evidence is	necessary and				
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessar 	overcome <u>all</u> rejections under appea y and was not earlier presented. S	al and/or appellant fa ee 37 CFR 41.33(d)(Is to provide a I).				
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attach	ned.				
11. The request for reconsideration has been considered bu	t does NOT place the application in	n condition for allowar	nce because:				
12. Note the attached Information Disclosure Statement(s). 13. Other:	(PTO/SB/08 or PTO-1449) Paper N	lo(s)					

Art Unit: 1634

DETAILED ACTION

ADVISORY ACTION

1. The proposed amendments filed on September 19, 2005 have been fully considered but will not be entered because they raise new issues that would require further consideration and/or search.

Response to Arguments

In pages 4 and 5 of applicant's remarks, applicant argues that the amendments have overcome the claim objections on claims 14-18 and 22-25 because no reference used in the rejections teach that "the nucleic acid should have an amino acid group".

This argument has been fully considered but it is not persuasive toward the withdrawal of the rejections because applicant's argument with respect to claims 14-18 and 22-25 is moot since applicant has amended claim 14. The proposed amendments in claim 14 raise new issues that would require further consideration and/or search. For example, although applicant incorporates the limitations of claim 19 and the phrase "said oligonucleotide or the polynucleotide having an amino group" from claim 21 into claim 14, applicant does not incorporate all limitations recited in claim 21 into claim 14, which is that said oligonucleotide or the polynucleotide has a functional group selected from the group consisting of an amino group, an aldehyde group, a thiol group and a biotin group. The scope of amended claim 14 is much narrower than that of the combination of claims 14, 19, and 21 filed on December 16, 2004. Furthermore, since the rejection on claim 21 in the office action mailed on March 17, 2005 is based on a nucleic acid having an aldehyde group and is not based on a nucleic acid having an amino group, incorporation of the phrase "said oligonucleotide or the polynucleotide having an amino group"

Application/Control Number: 10/737,328

Art Unit: 1634

Page 3

from claim 21 into claim 14 raises new issues that would require further consideration and/or

search.

2. Papers related to this application may be submitted to Group 1600 by facsimile

transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of

such papers must conform with the notices published in the Official Gazette, 1096 OG 30

(November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28,

1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is (571) 273-8300.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Frank Lu, Ph.D., whose telephone number is 571-272-0746. The

examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, W. Gary Jones, can be reached on (571) 272-0745.

Any inquiry of a general nature or relating to the status of this application should be

directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.

Frank Lu

PSA

October 4, 2005

ENNETH R. HORLICK, PH.D.
PRIMARY EXAMINER

10/4/05